XOMA Royalty (NASDAQ:XOMA) Issues Quarterly Earnings Results

XOMA Royalty (NASDAQ:XOMA) posted its quarterly earnings results on Wednesday. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.16, Zacks reports. XOMA Royalty had a net margin of 32.28% and a return on equity of 2.91%. The company had revenue of $13.76 million for the quarter, compared to the consensus estimate of $11.13 million.

Here are the key takeaways from XOMA Royalty’s conference call:

• Portfolio growth — XOMA added 22 assets in 2025 (now >120 total) and has seven commercial programs, with total portfolio receipts surpassing $50M and royalty receipts of $34M (up 68% year‑over‑year).
• Strong financials and cash returns — Full‑year GAAP revenue was $52.1M (vs. $28.5M in 2024) with GAAP net income of $31.7M, positive operating cash flow, ~$83M unrestricted cash at year‑end, and $16M returned via share buybacks (≈5% of shares).
• Dealmaking and platform optionality — A December revenue‑share with Takeda reallocated mezagitamab economics into potential low‑ to mid‑single‑digit royalties plus up to $853M of milestones across nine assets, and XOMA acquired Generation Bio platforms (ctLNP and iqDNA) intended for out‑licensing to generate future royalties/milestones.
• Clinical risk realized — Two portfolio Phase III programs (Rezolute in congenital hyperinsulinism and Gossamer’s seralutinib in PAH) failed to meet primary statistical thresholds, though both sponsors plan FDA discussions to pursue potential paths forward.
• Outlook and capital structure — Management says royalties could cover operating costs by 2027 if current trends continue, the Blue Owl loan is being amortized (could be repaid by 2030), and management may pursue refinancing or preferred optimization depending on future execution.

XOMA Royalty Price Performance

NASDAQ:XOMA traded up $0.84 during mid-day trading on Thursday, reaching $28.19. 25,468 shares of the stock were exchanged, compared to its average volume of 415,756. The company has a current ratio of 3.91, a quick ratio of 3.91 and a debt-to-equity ratio of 1.07. The business has a fifty day moving average price of $26.13 and a 200 day moving average price of $30.49. XOMA Royalty has a 1-year low of $18.35 and a 1-year high of $39.92. The firm has a market capitalization of $349.13 million, a PE ratio of 38.10 and a beta of 0.86.

Key Stories Impacting XOMA Royalty

Here are the key news stories impacting XOMA Royalty this week:

• Positive Sentiment: Q4 beat — XOMA reported $0.12 EPS (vs. consensus roughly negative) and $13.76M revenue, topping estimates and driving the immediate share lift. The results point to stronger royalty cash flows than expected. XOMA Royalty Jumps After Q4 Double Beat, Signals Pipeline Catalysts Ahead
• Positive Sentiment: Material growth in receipts — full‑year 2025 cash receipts topped $50M (royalties $33.6M; milestones $16.9M) and royalties rose ~68% vs. 2024, improving cash visibility for the company. XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
• Positive Sentiment: Management flagged pipeline catalysts — the earnings call/transcript highlights potential near‑term catalysts tied to partnered programs that could support future royalty streams and investor sentiment. XOMA Royalty Corporation (XOMA) Q4 2025 Earnings Call Transcript
• Positive Sentiment: Insider and analyst interest — filings reported the CEO purchased shares recently and several firms maintain buy/outperform calls with elevated price targets, supporting investor conviction. XOMA ($XOMA) Releases Q4 2025 Earnings
• Neutral Sentiment: Preferred dividend declared — the Board authorized cash dividends for Series A and B cumulative preferred shares (affects preferred holders; limited direct impact on common equity cash flow). XOMA Royalty Declares Quarterly Preferred Stock Dividends
• Negative Sentiment: Valuation/forward earnings risk — despite the quarter, consensus still shows negative EPS for the current fiscal year, which may cap multiple expansion until clearer recurring royalty growth or guidance is provided. (See company release and analyst notes above.)

Analysts Set New Price Targets

Several research firms have recently commented on XOMA. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of XOMA Royalty in a report on Monday, December 29th. TD Cowen upgraded shares of XOMA Royalty to a “hold” rating in a research report on Friday, February 13th. HC Wainwright cut their price target on XOMA Royalty from $104.00 to $97.00 and set a “buy” rating on the stock in a report on Thursday, December 11th. Stifel Nicolaus set a $50.00 price objective on XOMA Royalty in a report on Friday, December 12th. Finally, UBS Group set a $76.00 target price on XOMA Royalty in a research note on Tuesday, December 9th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, XOMA Royalty currently has an average rating of “Hold” and an average price target of $61.60.

Institutional Investors Weigh In On XOMA Royalty

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in XOMA Royalty by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 668,111 shares of the biotechnology company’s stock worth $25,749,000 after purchasing an additional 29,298 shares in the last quarter. Opaleye Management Inc. boosted its holdings in shares of XOMA Royalty by 14.7% in the fourth quarter. Opaleye Management Inc. now owns 292,590 shares of the biotechnology company’s stock worth $7,780,000 after buying an additional 37,503 shares during the period. Geode Capital Management LLC increased its position in shares of XOMA Royalty by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 221,566 shares of the biotechnology company’s stock worth $5,893,000 after acquiring an additional 9,589 shares in the last quarter. Woodline Partners LP raised its holdings in shares of XOMA Royalty by 16.5% during the third quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company’s stock valued at $8,091,000 after acquiring an additional 29,715 shares during the period. Finally, State Street Corp lifted its position in shares of XOMA Royalty by 4.7% in the 4th quarter. State Street Corp now owns 174,908 shares of the biotechnology company’s stock valued at $4,651,000 after acquiring an additional 7,873 shares in the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.